Care Options

Nu.Q Canine Cancer Screening Blood Test

The Nu.Q Vet Cancer Screening Test is designed to help veterinarians identify dogs that may have cancer before obvious symptoms appear.

Key takeaways

Nu.Q is a canine cancer screening blood test that measures circulating nucleosomes to identify possible signs of certain cancers, but it cannot diagnose or rule out cancer.

  • The Nu.Q Vet Cancer Screening Test is designed to help veterinarians identify dogs that may have cancer before obvious symptoms appear.
  • It measures substances called nucleosomes in a blood sample.
  • Elevated levels can raise suspicion of cancer, particularly lymphoma and hemangiosarcoma, but other health conditions can also cause elevations.
  • For dog owners considering this test, the important questions are whether it is appropriate for their dog's age and health, how reliable the results are, what a positive result means, and what happens next.

What Is the Nu.Q Canine Cancer Screening Blood Test?

Nu.Q is a blood-based screening test developed to measure circulating nucleosomes in dogs.

Nucleosomes are small structures made of DNA wrapped around proteins called histones. They help organize DNA inside cells. When cells die, nucleosomes can enter the bloodstream. Certain cancers cause increased cell death and turnover, which can result in higher circulating nucleosome concentrations.

The Nu.Q test uses an antibody-based laboratory method called an enzyme-linked immunosorbent assay (ELISA) to measure these substances in plasma. It specifically measures H3.1-associated nucleosomes.

The test works as follows:

1. A veterinarian collects a blood sample from the dog.

2. The blood is processed to separate the plasma.

3. The Nu.Q assay measures the concentration of circulating nucleosomes.

4. The result helps the veterinarian assess whether further cancer investigation may be appropriate.

The test does not directly identify cancer cells, locate a tumor, or determine the type of cancer. It measures a biological signal that can be associated with certain cancers.

Which Dogs May Benefit From Nu.Q Testing?

Nu.Q is primarily intended for apparently healthy dogs undergoing routine preventive care, rather than dogs already showing signs of illness.

The manufacturer's recommendations include:

• Dogs aged 7 years and older: Older dogs may benefit from discussing cancer screening during their annual wellness examinations.

• Dogs aged 4 years and older with increased cancer risk: Certain breeds and dogs with a family history of cancer may warrant earlier screening.

Breeds identified as having increased cancer risk include:

• Labrador Retrievers

• Golden Retrievers

• German Shepherds

• Boxers

• Rottweilers

• Beagles

• French Bulldogs

• Bernese Mountain Dogs

• Siberian Huskies

• Great Danes.

Breed alone does not establish that a dog has cancer or necessarily needs this particular test. A veterinarian can consider age, family history, physical examination findings, and overall health when discussing screening.

Important distinction: Nu.Q is designed for screening apparently healthy dogs. Conditions such as sepsis, trauma, immune-mediated disease, and other inflammatory conditions can increase nucleosome concentrations and complicate interpretation. The manufacturer does not recommend using the test as a cancer screening tool when these conditions may be present.

Nu.Q on the Element i+ analyzer has been validated for dogs, not cats or other animal species.

How Accurate Is the Nu.Q Cancer Test?

Nu.Q has published clinical research supporting its ability to detect elevated nucleosome concentrations in dogs with certain cancers.

However, its performance varies considerably depending on the cancer type.

A 2022 study published in BMC Veterinary Research evaluated circulating nucleosome concentrations in dogs with several common cancers and healthy dogs. At a selected threshold, researchers reported:

• 49.8% sensitivity: The test identified elevated nucleosome levels in approximately half of the cancer cases evaluated.

• 97% specificity: Approximately 97% of the healthy comparison dogs did not have an elevated result.

These figures describe different aspects of test performance. They do not mean that a dog with a positive result has a 97% chance of having cancer.

The probability that an elevated result represents cancer also depends on the dog's underlying likelihood of having the disease. This is particularly important when testing apparently healthy dogs.

Which cancers does Nu.Q detect best?

The published study found differences in detection rates across cancer types. At the selected 97% specificity threshold, the reported sensitivities included:

• Cancer type — Detection sensitivity

• Hemangiosarcoma — 82%

• Lymphoma — 77%

• Histiocytic sarcoma — 54%

• Malignant oral melanoma — 50%

• Osteosarcoma — 35%

• Soft tissue sarcoma — 29%

• Mast cell tumors — 19%

These results show why Nu.Q should not be treated as a comprehensive cancer screening solution.

It performed better for certain systemic cancers, particularly lymphoma and hemangiosarcoma, than for several localized tumors. A dog can have cancer and still receive a low Nu.Q result.

The American Animal Hospital Association's 2026 oncology guidelines also emphasize that no blood or urine screening test can conclusively confirm or exclude cancer in veterinary patients. The available evidence is not yet sufficient to establish that these screening tests meaningfully improve outcomes for animals.

What Do Low, Moderate, and High Nu.Q Results Mean?

Nu.Q results are interpreted according to the concentration of circulating nucleosomes.

Depending on the testing system, results may be described using categories such as low, moderate, or high suspicion.

The categories help guide the next steps, but none independently establishes a cancer diagnosis.

Low result

A low result indicates that the measured nucleosome concentration is consistent with a lower likelihood of cancers known to increase circulating nucleosomes.

However, a low result does not mean the dog is cancer-free.

Some cancers do not consistently release enough nucleosomes into the bloodstream to produce an elevated result. This is particularly relevant for mast cell tumors, osteosarcoma, and soft tissue sarcomas.

If a dog has a suspicious lump, unexplained symptoms, or abnormal findings during a physical examination, further investigation may still be necessary.

Moderate result

A moderate result indicates an intermediate level of concern that needs additional interpretation.

Possible contributing factors include:

• Whether the dog had eaten before the blood sample was collected.

• Sample collection and processing problems.

• Inflammation or other underlying health conditions.

• Increased cellular turnover unrelated to cancer.

For Antech's in-house Element i+ test, fasting is not required before the initial test. However, if a dog that was not fasted receives a moderate or high result, the manufacturer recommends considering a new fasted sample and repeating the test.

The veterinarian can determine whether repeating the test is appropriate or whether the dog's history and examination findings warrant further investigation immediately.

High result

A high result indicates increased circulating nucleosome concentrations and raises suspicion for certain cancers, particularly lymphoma and hemangiosarcoma.

However, elevated nucleosomes can also occur with tissue damage, sepsis, trauma, and inflammatory or immune-mediated conditions. The test cannot distinguish these causes from cancer.

A high result should prompt a discussion about additional diagnostic testing rather than an assumption that cancer is present.

The numerical result also does not necessarily indicate how advanced or severe a cancer is. Nu.Q is not designed to predict survival or provide a cancer prognosis.

What Happens After an Abnormal Nu.Q Result?

An abnormal result is a reason to investigate further, not a reason to assume the worst.

The next steps depend on the dog's medical history, physical examination, symptoms, and other test results.

1. Review the dog's health history

The veterinarian should consider recent illness, inflammation, injury, existing medical conditions, and medications.

Certain medications, including corticosteroids, may affect nucleosome concentrations and influence interpretation. Owners should provide an accurate medication history rather than stopping prescribed treatments independently.

2. Consider repeating the blood test

If the result is moderate or potentially affected by food intake or sample handling, a repeat test may help clarify whether the elevation persists.

For a non-fasted dog with a moderate or high result on the Antech in-house test, the manufacturer recommends considering a repeat sample after fasting.

3. Perform additional diagnostic tests

If the result remains elevated or other findings raise concern, the veterinarian may recommend additional investigations.

Depending on the suspected problem, these may include:

• Complete blood count.

• Blood chemistry testing.

• Urinalysis.

• Chest X-rays.

• Abdominal ultrasound.

• Fine-needle aspiration of a suspicious mass or lymph node.

• Biopsy and tissue examination.

Imaging can help identify suspicious masses and assess possible cancer spread. Cytology or histopathology can provide the information needed to establish a tumor diagnosis.

4. Discuss the findings and available options

If cancer is confirmed, the next decisions depend on the tumor type, location, grade, stage, and the dog's overall health.

The 2026 AAHA oncology guidelines emphasize the importance of obtaining an appropriate tumor diagnosis and staging information when developing a treatment plan.

Not every suspicious finding leads to a cancer diagnosis, and an elevated Nu.Q result alone should not determine treatment decisions.

Warning Signs That Need Veterinary Attention

Nu.Q is not a replacement for recognizing changes in a dog's health.

Some cancers, including hemangiosarcoma, can produce few obvious symptoms during their early development. Other dogs may show nonspecific changes such as weakness, lethargy, reduced appetite, or reduced tolerance for exercise.

Contact a veterinarian promptly if a dog develops:

• Persistent or unexplained weakness.

• Reduced appetite.

• Unusual tiredness or lethargy.

• Reduced ability or willingness to exercise.

• New bruising or unusual skin masses.

• A lump that changes or grows.

Seek emergency veterinary care immediately if a dog collapses, develops severe weakness, has pale gums, or experiences rapid or difficult breathing. These can be signs of serious internal bleeding associated with hemangiosarcoma.

A dog experiencing these symptoms needs immediate assessment, not a routine cancer screening appointment.

What Should You Ask Before Paying for Nu.Q Screening?

Before scheduling the test, consider discussing the following with the veterinarian:

• Is the dog's age, breed, or family history a reason to consider screening?

• Is the dog healthy enough for a screening test to provide useful information?

• Which cancers is the particular Nu.Q test most likely to detect?

• What happens if the result is moderate or high?

• What additional tests might be necessary?

• How much could the complete follow-up investigation cost?

The cost of Nu.Q itself is only one consideration. An abnormal result can lead to additional bloodwork, imaging, and potentially invasive diagnostic procedures. The AAHA guidelines recommend weighing the potential benefits and limitations of cancer screening tests before using them.

There is no single price that applies to every veterinary practice. Ask the clinic for its current test price and whether additional diagnostic costs would be separate.

Frequently asked questions

Is Nu.Q a cancer diagnosis test or a screening test?

Nu.Q is a screening test. It measures circulating nucleosomes to identify dogs that may have certain cancers, but an elevated result does not establish a cancer diagnosis. Additional diagnostic testing is necessary.

Can Nu.Q detect cancer before symptoms appear?

Nu.Q is intended to help identify possible current cancer in apparently healthy dogs during routine wellness examinations. Its ability to detect cancer depends on the type and biological behavior of the tumor. It cannot guarantee detection before symptoms develop.

Can Nu.Q detect all types of canine cancer?

No. The published study found substantial differences in detection sensitivity across cancer types. The test performed better for lymphoma and hemangiosarcoma than for mast cell tumors, osteosarcoma, and soft tissue sarcomas.

Does a negative Nu.Q result mean a dog does not have cancer?

No. A low result does not rule out cancer. The overall sensitivity reported in the published study was 49.8%, meaning many cancer cases did not produce elevated nucleosome concentrations.

Can Nu.Q identify the location of a tumor?

No. Nu.Q measures circulating nucleosome concentrations but cannot identify the location or type of cancer. Imaging and additional diagnostic procedures may be needed to locate and characterize a suspicious tumor.

Can Nu.Q predict whether a dog will develop cancer?

No. Nu.Q measures a biological signal associated with certain cancers that may already be present. It cannot predict whether a dog will develop cancer in the future.

Does a dog need to fast before a Nu.Q blood test?

It depends on the testing system. Antech states that fasting is not required before its initial in-house test, but a moderate or high result in a non-fasted dog may prompt a repeat test using a fasted sample. Follow the veterinarian's instructions for the specific test being performed.

Is Nu.Q available for cats?

The Nu.Q test on the Element i+ analyzer is validated for dogs. The manufacturer reports that there are no published studies validating its use in other species.

Editorial standards

Who wrote this guide

Written by VetWayfinder Editorial Team.

Every factual statement is tied to a cited source listed below. Report an error through the corrections page.